Fig. 5: The drug-pathway-target-disease network of valbenazine, deutetrabenazine and vitamin E for the treatment of TD. | Schizophrenia

Fig. 5: The drug-pathway-target-disease network of valbenazine, deutetrabenazine and vitamin E for the treatment of TD.

From: Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia

Fig. 5

Drug-pathway-target-disease network diagrams relating to the effects of valbenazine (A), deutetrabenazine (C), and vitamin E (E) on TD. The orange inverted triangles represent the drug and disease. The green round rectangles represent the pathways affected by three agents in the treatment of TD, while the red rounded rectangles represent the critical pathways. The blue circles represent the targets of these three agents associated with the treatment of TD. The red triangles represent core targets. B The distribution of the six selected core targets (DRD1, DRD2, DRD3, MAOB, SLC6A3, and SLC18A2) in the dopaminergic synapse signaling pathway. D The distribution of the six selected core targets (DRD1, DRD2, MAOA, MAOB, SLC6A3, and SLC18A2) in the dopaminergic synapse signaling pathway. (F) The distribution of the five selected core targets (AKT1, BDNF, INS, NOS3, and TLR4) in the PI3K-Akt signaling pathway.

Back to article page